AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model

Molecular Therapy : the Journal of the American Society of Gene Therapy
Melvin M EversPavlina Konstantinova

Abstract

Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Previously, we showed strong huntingtin reduction and prevention of neuronal dysfunction in HD rodents using an engineered microRNA targeting human huntingtin, delivered via adeno-associated virus (AAV) serotype 5 vector with a transgene encoding an engineered miRNA against HTT mRNA (AAV5-miHTT). One of the challenges of rodents as a model of neurodegenerative diseases is their relatively small brain, making successful translation to the HD patient difficult. This is particularly relevant for gene therapy approaches, where distribution achieved upon local administration into the parenchyma is likely dependent on brain size and structure. Here, we aimed to demonstrate the translation of huntingtin-lowering gene therapy to a large-animal brain. We investigated the feasibility, efficacy, and tolerability of one-time intracranial administration of AAV5-miHTT in the transgenic HD (tgHD) minipig model. We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression. Both human mutant huntingtin mRNA and protein ...Continue Reading

Citations

Jul 14, 2020·Expert Opinion on Biological Therapy·Melvin M Evers, Pavlina Konstantinova
Apr 20, 2019·Frontiers in Molecular Biosciences·Talya ShachamGerardo Z Lederkremer
Oct 28, 2019·Disease Models & Mechanisms·Taras ArdanZdenka Ellederová
Sep 16, 2020·Pharmacological Reviews·Ai-Ming YuMei-Juan Tu
Sep 15, 2020·Journal of Huntington's Disease·David HowlandJodi McBride
Dec 14, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Vivek Sudhakar, R Mark Richardson
Nov 7, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mengtian CuiWei Ding
Mar 18, 2020·Der Nervenarzt·A MühlbäckG B Landwehrmeyer
Aug 4, 2020·Expert Opinion on Investigational Drugs·Roger A BarkerDavid C Rubinsztein
Aug 17, 2020·Nature Reviews. Neurology·Sarah J TabriziEdward J Wild
May 18, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Rula Zain, C I Edvard Smith
Jul 14, 2020·Current Opinion in Neurology·Carlos Estevez-FragaSarah J Tabrizi
Jul 10, 2019·Annual Review of Neuroscience·C Frank BennettDon W Cleveland
Oct 20, 2020·Frontiers in Neuroscience·Raygene Martier, Pavlina Konstantinova
Dec 15, 2020·Biomaterials Science·João ConniotJoão Conde
Jan 3, 2021·Wiley Interdisciplinary Reviews. RNA·Anna Kotowska-ZimmerMarta Olejniczak
Feb 19, 2019·Molecular Therapy. Nucleic Acids·Raygene MartierPavlina Konstantinova
Oct 27, 2020·Frontiers in Aging Neuroscience·Paulina Troncoso-EscuderoRene L Vidal
Dec 19, 2020·Scientific Reports·Valentina FodaleAlberto Bresciani
Feb 3, 2021·Nature Neuroscience·Jichao Sun, Subhojit Roy
Feb 21, 2021·Journal of Pharmacological and Toxicological Methods·Joachim MaxeinerJaya Krishnan
Apr 22, 2021·Journal of Neuroscience Research·Margarida BeatrizAna Cristina Carvalho Rego
Apr 12, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Defne A Amado, Beverly L Davidson
May 1, 2021·International Journal of Molecular Sciences·Hanadi AnanbehHelena Kupcova Skalnikova
May 18, 2021·Molecular Therapy. Methods & Clinical Development·Peng GuWeiwang Gu
Jun 14, 2021·Molecular Genetics and Metabolism·Valeria BertaniAnna Maria Cantoni
Aug 21, 2021·Journal of Biomedical Science·Chih-Wei TungShang-Hsun Yang
Aug 24, 2021·Frontiers in Cellular Neuroscience·Xiaoyu Dong, Shuyan Cong
Aug 28, 2021·International Journal of Molecular Sciences·Amy KimJoana Gil-Mohapel
Jan 1, 2020·Molecular Therapy. Methods & Clinical Development·David L HaggertyBrady Atwood
Aug 21, 2021·Frontiers in Bioengineering and Biotechnology·Kimberly L PieterszBas Blits
Nov 12, 2021·Der Nervenarzt·Wiebke FrankG Bernhard Landwehrmeyer
Sep 10, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·Stefano EspinozaStefano Gustincich

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides
transgenic
biopsies
PCR
ELISA

Software Mentioned

forcats
broom
xPonent
R
Fiji ImageJ
cowplot
tidyverse
uniQure
lme4
stringr

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.